

# Trust in AI in Health Care: Opportunities rather than Risks

Andre Dekker


Medical Physicist | Professor of Clinical Data Science

Maastricht UMC+ | Maastricht University | Maastro Clinic


4th ISACA Risk Event

Responsible AI | Podium II | Bussum | November 16, 2023 | 15:10-15:55

# Prediction of survival





# Hey, ChatGPT Doctor: can I trust you?



Lung Cancer  
2 year survival  
158 patients  
5 MDs  
Prospective  
**AUC: 0.56**


- Explosion of data
- Explosion of decisions
- Explosion of 'evidence'
  - Too much to read
  - 3 % in trials, bias
  - Sharp knife



Oberije et al. , Radiother Oncol. 2014; 112: 37–43 / J Clin Oncol 2010;28:4268 / JMI 2012 Friedman, Rigby / BMJ Clinical Evidence


# Potential of Artificial Intelligence

## Learning Health Care System – Faster Innovations & Better Outcomes



# Data

# Big Data? – An example from cancer



**Oncology**  
 2007-2017  
 150M patients  
 0.1-10GB per patient

**15-1500PB**  
**80% unstructured**

**Hospitals**  
 China: 25.000  
 India: 35.000  
 Germany: 2.000  
 France: 2.300  
 Italy: 1.100  
 USA: 5.500  
 Australia: 1.400  
**TOTAL ~100.000**

# Barriers to sharing data

[..] the problem is not really technical [...]. Rather, the problems are **ethical, political, and administrative**.

*Lancet Oncol 2011;12:933*

1. Administrative (I don't have the resources)
2. Political (I don't want to)
3. Ethical (I am not allowed to)
4. Technical (I can't)



# A different approach


If sharing is the problem: Don't share the data

If you can't bring the data to the research

You have to bring the research to the data

## Challenges

- The research application has to be distributed (trains & track)
- The data has to be understandable by an application (i.e. not a human) -> FAIR data stations



[www.personalhealthtrain.nl](http://www.personalhealthtrain.nl)






# Personal Health Train (2015)



# Federated FAIR Data and Learning Infrastructure




## Simple example


Brussels	Frankfurt	Maastricht	Oslo	Leeds	Milan
87	62	83	46	70	76
69	69	56	49	90	64
	47	72	56	93	73
	73	84	95	72	
	59	63	58	60	
	49		72	47	
	62		53	62	
			81	94	
			73		

N=34  
Mean Age = 68.2y

$$\frac{2 \times 78.0 + 7 \times 60.1 + 5 \times 71.6 + 9 \times 64.8 + 8 \times 73.5 + 3 \times 71.0}{2 + 7 + 5 + 9 + 8 + 3} = 68.2$$

# euroCAT example






Open Source (vantage6): [distributedlearning.ai](https://distributedlearning.ai)


# Learning



# General AI (model) approach



# Machine Learning



Slide courtesy of Kristy Brock



Slide (and dog) courtesy of Kristy Brock



Ears

Eyes

Fur



Paws

Tail

**NOT A CAT!**

**Cat: 97%**

# Deep Learning – Human out of the loop



Slide courtesy of Kristy Brock


# Regulatory & Contracts

*Nat Biomed Eng 2018;2:719*




**Table 3 | Comparisons between human evaluations and different types of AI approaches**

Approaches	Model comprehensibility	Performance	Reproducibility	Dependency on prior knowledge	Development and training costs <sup>a</sup>	Running costs	Around-the-clock availability	Update costs
Human evaluation	High	Moderate or high	Moderate	High	High	High	Low	High
Rule-based algorithms	High	Moderate or high	High	High	Moderate or high	Low	High	High
Feature-based machine-learning methods	Moderate or high	Moderate or high	High	Moderate <sup>b</sup>	Moderate	Low	High	Moderate <sup>c</sup>
Deep artificial neural networks	Low or moderate	High	High	Low	Moderate	Low	High	Low



**CE marked AI for Radiology**




"If the transition to the MDR continues at this pace, half of the AI products for radiology can no longer be used clinically after May 2024."




# Applications



# AI for Better Health Care





# AI for Better Processes




# Artificial Intelligence is different than Human Intelligence


*AI algorithms cannot be expected to perform at a higher level than their training data, but should deliver the same standard of performance consistently for data within the training space.*



CT prone  
All training data was supine



AI will find you a  
liver anywhere...



Images courtesy of MD Anderson / Brian M. Anderson  
Nature 2020, 577:89 | JASON, Artificial Intelligence for  
Health and Health Care, Dec 2017, JSR-17-Task-002



# Hey, ChatGPT: can I trust you?

AN

Please explain the toxic effects of lung radiotherapy used for STage III lung cancer

1. Fatigue
2. Radiation dermatitis
3. Radiation pneumonitis
4. Radiation esophagitis
5. Radiation-induced nausea and vomiting
6. Hair loss

1. Fatigue: Radiotherapy can induce severe fatigue and exhaustion in patients. This fatigue may persist throughout the treatment period and impact daily activities and overall quality of life.
2. Radiation dermatitis: The skin in the treated area can experience radiation-induced dermatitis, characterized by redness, dryness, and irritation. The skin may become sensitive and itchy. Proper skincare and the use of prescribed moisturizers can help alleviate these symptoms.
3. Radiation pneumonitis: Radiation therapy can cause inflammation in the lungs, leading to radiation pneumonitis. This condition manifests as a cough, shortness of breath, and chest discomfort. It typically occurs within a few months after treatment initiation and can be managed with anti-inflammatory medications.
4. Radiation esophagitis: The esophagus, the tube connecting the mouth to the stomach, may become inflamed and swollen due to radiation. This can result in painful swallowing, difficulty eating, and, in some cases, the development of ulcers. Medications and dietary modifications are often recommended to alleviate these symptoms.
5. Radiation-induced nausea and vomiting: Some individuals may experience nausea and vomiting as a result of radiation therapy. Antiemetic medications can be prescribed to control these side effects and minimize their impact.
6. Hair loss: In certain cases, localized hair loss may occur in the treated area, although it is important to note that hair loss specifically on the head is not a common side effect of lung radiotherapy.



# Better – Processes – NLP

The screenshot displays a software interface for processing medical reports. On the left, an 'Annotated Report' shows a text snippet from a radiology report with various words highlighted in yellow (e.g., 'Possible', 'No', 'Small', 'No indication'). A legend below the report indicates that green highlights mean 'Present', blue means 'Involved', yellow means 'Context Modifier', and grey means 'Context Target'. On the right, a 'TNM-8 Lung' classification panel is shown. It includes a language dropdown set to 'English', a 'Classify' button, and dropdown menus for T stage (set to 'T3'), N stage (set to 'N0'), and M stage (set to 'M'). Below these, there are input fields for tumor size (4.7 cm), a 'Present' checkbox, a checked 'Satellite Nodule (T3)' checkbox, and a 'Pathologic Lymph Nodes' checkbox. The bottom of the interface indicates it is 'POWERED BY TINY'.



From the provided radiology report, we can extract the T and N stages as follows:

T (Tumor):

- The tumor is located in the left upper lobe of the thorax.
- The maximum size of the tumor is estimated at 4.7 × 3.0 cm.

N (Node):

- Satellite nodes are visible at station 8-41 with an estimated size of 1.3 cm.
- A lymph node is visible at station 7 with a size of approximately 5.2 cm.
- No lymph nodes are visible on the contralateral side.

Based on the information in the report, the T stage is T2 (since the tumor size exceeds 3 cm but is 5 cm or less), and the N stage would be N2 (due to the presence of lymph nodes in station 7 and satellite nodes). However, the complete TNM stage would also depend on

**NEWS**

8 Comments

# Texas professor flunked whole class after ChatGPT their papers it wrote

By **Natalie O'Neill**

May 18, 2023 | 3:05pm | Updated

# Do AIs need to be perfect?




*AI algorithms cannot be expected to perform at a higher level than their training data, but should deliver the same standard of performance consistently for data within the training space.*

JASON, Artificial Intelligence for Health and Health Care, Dec 2017, JSR-17-Ta

# Trust in model vs own expertise



# AI for Better Health Care



# Small Cell Lung Cancer – Shared Decision Making – Grey Area Guideline

Maestro Desktop Artsen - Clinic Revenier

Keyman B.V. - Altes - H&E PRODUCTS - 63 H&E - H&E - ChySoft

M. Castenmans-Testmike  
1000004

http://www.digipatient.nl/patienten/artsen/maestro/patient-id:1000004

Patient: 1000004

Tumor: P1: maligne neoplasma van long

Geslacht: Vrouw

cM-stadium: M1b (>1 metastase)

cN-stadium: cN0, cN1 of cN2

Hb (mmol/liter): 6.2

LDH (U/L): 1600

Kans op overleving langer dan 26 weken:  
53 %

Opslaan Reset



Short survival – no PCI?



Experience patient:  
Decisional Conflict, Control  
Preference, SDM



Experience MD,  
SDM



Cost Effectiveness;  
Care path



# Better Outcomes – Prediabetes



## PREDIABETES RISK SCORE

NAME: SAIRAM      AGE: 22      LOCATION: PALAKOL  
 UHID: 123456789      GENDER: MALE      DATE OF REPORT: 10-11-2021

### PATIENT RISK SCORE

Risk      Score  
**Low Risk**      80

### INFORMED CONSENT: YES

Height	147	Weight	58
BMI	26.84	Diet	Non-Veg
Alcohol	No	Waist Circumference	34
Change in Body Weight	Same	Physical Activity	Mild
Family History of Diabetes	Yes	Dyslipidemia	No
Hypertension	Yes	Symptoms	No
Past Medical History	No		

### RECOMMENDED PROTOCOL

#### Activity

Increase physical activity. Should aim for 30 minutes of moderately intense exercise (such as a brisk walk) most days of the week, for a minimum of 150 minutes (2.5 hours) of total physical activity per week.


#### Nutrition

Low Carbohydrate, Low Fat diet

#### Referral to consultant

Not Required

AUC~0.8



# Better Outcomes – Self-medication in Chronic Heart Failure

**AID-HF** English Nederlands

Do you feel short of breath when lying down (orthopnea)? ⓘ

None Slight Moderate Severe

Do you have a dry cough? ⓘ

None Slight Moderate Severe

Do you have swelling (edema)? ⓘ

None Slight Moderate Severe



Do you feel dizzy? ⓘ

None Slight Moderate Severe

Do you feel like fainting? ⓘ

Yes No

Reset Submit





## Better Outcomes – Model Based Indication




## Some things to get you thinking

# Typical Data Quality challenges

声门下区

- Data are unstructured
- Data are not understandable
- Data are missing
- Data are incorrect
- Data are contradicting
- Data are biased
- Data are biased missing
- Garbage in – Garbage out?



T4N0M0 Stage IV patient

Patient weighing 1000kg

Grade 3+ toxicities



# Who is this?



## Pressure-Volume Loops in Cardiac Surgery

### Proefschrift


ter verkrijging van de graad van doctor  
aan de Universiteit Maastricht,  
op gezag van de Rector Magnificus,  
Prof.dr. A.C. Nieuwenhuijzen Kruseman,  
volgens het besluit van het College van Decanen,  
in het openbaar te verdedigen,  
op vrijdag 12 september 2003 om 14:00 uur

door


André Dekker



# Good enough for AI




# Garbage in — Garbage out



**Regulations:** Application approval; validation; audits; community-based challenges; analyses of biases, fairness and diversity



# Good enough for AI



# FaceAge

## a | FaceAge Algorithm



## b | Data

### Discovery Datasets (n=58,851)

#### Training Dataset | IMDB-WIKI


56,104 famous and healthy individuals

Manually curated and focused on older individuals

#### Technical Validation | UTK


2,547 healthy individuals with matched ages and ethnicity labels

## c | Clinical Experiments



### Number at risk

FaceAge $\leq 65$	1385	1067	861	700	536	409	250	128
$65 < \text{FaceAge} \leq 75$	2035	1565	1300	1062	815	634	419	228
$75 < \text{FaceAge} \leq 85$	1292	983	791	628	487	377	259	153
FaceAge $> 85$	194	143	114	88	64	49	32	17



Zalay et al. medRxiv. 2023 Sep 12;2023.09.12.23295132.



## Key messages

- We need AI for better processes and better outcomes in health care
- Trends
  - FAIR Federated Data Infra
  - Deep learning
  - Companion AI for better indications & shared decision making
- Cautions
  - Bias | Causality | Culture | Quality | Ethics
- What is responsible and what is compliant?
  - Irresponsible is not to share data and not to develop AI
  - Compliance in terms of privacy is clear, other ELSI less so

# Acknowledgements

## Netherlands

MAASTRO, Maastricht, Netherlands  
 Radboudumc, Nijmegen, Netherlands  
 Erasmus MC, Rotterdam, Netherlands  
 Leiden UMC, Leiden, Netherlands  
 Elizabeth Twee Steden Ziekenhuis,  
 Tilburg, Netherlands  
 Catharina Hospital, Eindhoven,  
 Netherlands  
 Isala Hospital, Zwolle, Netherlands  
 NKI Amsterdam, Netherlands  
 UMCG, Groningen, Netherlands  
 IKNL, Utrecht, Netherlands

## Europe

Policlinico Gemelli & UCSC, Roma, Italy  
 UH Ghent, Belgium  
 UZ Leuven, Belgium  
 Cardiff University & Velindre CC, Cardiff,  
 UK  
 CHU Liege, Belgium  
 Uniklinikum Aachen, Germany  
 LOC Genk/Hasselt, Belgium  
 The Christie, Manchester, UK  
 State Hospital, Rovigo, Italy  
 St James Institute of Oncology, Leeds,  
 UK  
 U of Southern Denmark, Odense,  
 Denmark  
 Greater Poland Cancer Center, Poznan,  
 Poland  
 Oslo University Hospital, Oslo, Norway

Aarhus Universitetshospital, Aarhus,  
 Denmark  
 Bank of Cyprus Oncology Center, Nicosia,  
 Cyprus  
 Weston Park Hospital, Sheffield, UK  
 Hull University Teaching Hospitals NHS  
 Trust, Hull, UK  
 Addenbrookes' Hospital, Cambridge, UK  
 Oxford University Hospitals NHS  
 Foundation Trust, Oxford, UK  
 Haukeland University Hospital, Bergen,  
 Norway

## Africa

University of the Free State,  
 Bloemfontein, South Africa

## Asia

Fudan Cancer Center, Shanghai, China  
 CDAC, Pune, India  
 Tata Memorial, Mumbai, India  
 Suining Central Hospital, Suining, China  
 HGC Oncology, Bangalore, India  
 MVRCC&NITC, Calicut, Kerala, India  
 Apollo Hospitals, Hyderabad, India  
 CMC Vellore, Vellore, India  
 Tianjin Medical University, Tianjin, China  
 Cancer Hospital of Shantou University,  
 Shantou, China  
 Guangdong Provincial People's Hospital,  
 Guangzhou, China  
 Zhejiang Cancer Hospital, Hangzhou,

## China

## North America

RTOG, Philadelphia, PA, USA  
 MGH, BWH, Harvard, Boston, MA, USA  
 University of Michigan, Ann Arbor, USA  
 Princess Margaret CC, Canada  
 Ottawa Hospital Research Institute,  
 Ottawa, Canada

## South America

Albert Einstein, Sao Paulo, Brazil

## Australia

University of Sydney, Australia  
 Westmead Hospital, Sydney, Australia  
 Liverpool and Macarthur CC, Australia  
 ICCC, Wollongong Australia  
 Calvary Mater, Newcastle, Australia  
 North Coast Cancer Institute, Coffs  
 Harbour, Australia

## Industry

Varian, Palo Alto, CA, USA  
 Philips, Bangalore, India  
 Soharc GmbH, Fuerth, Germany  
 Microsoft, Hyderabad, India  
 Mirada Medical, Oxford, UK  
 CZ Health Insurance, Tilburg, NL  
 Siemens, Malvern, PA, USA  
 Roche, Woerden, NL  
 IQVIA, London, UK



Thank you for your attention